Australian drug development company Emyria (ASX:EMD) has announced the appointment of consultant psychiatrist Dr Richard Magtengaard to its medical advisory board.
Emyria’s managing director, Dr Michael Winlo, said, “We’re delighted to add Dr Magtengaard to our esteemed Medical Advisory Board. Dr Magtengaard is a highly respected psychiatrist with expertise in mood disorders, chronic pain and PTSD.
"Dr Magtengaard has a particular passion for improving care for Australian military veterans and for using technology and innovation to improve care delivery. Dr Magtengaard’s appointment boosts Emyria’s expertise in mental health as we progress our own drug development, care model design and clinical research into the growing global health concern of mental health.”
Dr Magtengaard added, “I’m passionate about improving mental health, particularly for those who serve. Tackling the growing challenge of mental health will require new technologies, treatments and data-backed ways of caring for patients. Emyria is leading some great initiatives in these areas which is why I’m excited to support their mission."